Impact Factor
3.79
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.96
1,622 total citations
h5-index
33
h5 depth signal
Cited share
79.8%
348 of 436
Total citations
1,622
Citation footprint
Metric signal
3.72
External metric anchor
Self-citation
5.2%
85 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
449
Italy
166
United Kingdom
149
China
148
Germany
137
Citing Fields of Research
Brain Neurological Disorders
1,206
Neurosciences
112
Neurodegenerative Disorders
37
Cytogenetics
34
Neurodevelopmental Disorders
34
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,397
Articles tracked across the journal lifetime
Indexed publication set
436
348 cited publications
Last 12 months
213
17.8 publications/month
Open access share
100.0%
213 OA publications in the last year
Leading citing country
United States
449 citing publications
Leading citing field
Brain Neurological Disorders
1,206 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v6n1, Mar. 2021-
v1n1/2, Sept. 2016-
Active Coverage
Research Focus & Classification
Indexed Subjects
Brain Neurological Disorders
Issuing & Sponsoring Bodies
issuing body
International League against Epilepsy
Broad Categories
Neurology
Brain Neurological Disorders
MeSH Descriptors
Epilepsy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/epi4.70368
Open DOI
Early neurocognitive outcomes following SEEG with radiofrequency thermocoagulation
Objective: Characterization of early neuropsychological outcomes following SEEG with radiofrequency thermocoagulation (RFTHC) is essential to guide patient expectations around return to work, study, and caregiving. The current study aime...
02
DOI 10.1002/epi4.70373
Open DOI
Progressive Hippocampal Volume Reduction Beyond Normal Aging in Temporal Lobe Epilepsy: A Longitudinal MRI Study
Recent neuroimaging studies have suggested that epilepsy may show progressive brain structural changes over time. However, longitudinal hippocampal volume changes in temporal lobe epilepsy (TLE) have not been adequately compared with tho...
03
DOI 10.1002/epi4.70372
Open DOI
The translational asymmetry of corpus callosotomy: Two literatures that answered different questions
Corpus callosotomy is an established palliative operation for drug‐resistant epilepsy dominated by drop attacks, and it is performed in three extents: anterior, usually of the anterior two‐thirds; total, in one or two stages; and selecti...
04
DOI 10.1002/epi4.70371
Open DOI
Issue Information
05
DOI 10.1002/epi4.70360
Open DOI
Epilepsia Open —October 2026 Announcements
06
DOI 10.1002/epi4.70370
Open DOI
Reversal of refractory epilepsy in an adult with GAMT deficiency: A case report and comparative literature review
Objective: Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive creatine biosynthesis disorder. Reports specifically focusing on adult patients remain scarce. Methods: We report a 52‐year‐old female (the old...
07
DOI 10.1002/epi4.70361
Open DOI
The basal ganglia and the epilepsies
The basal ganglia are an evolutionarily conserved neural circuit best known for the selection and sequencing of voluntary movement. Increasing evidence, however, indicates that these structures also play an important role in regulating p...
08
DOI 10.1002/epi4.70359
Open DOI
Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care
Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of the most severe epilepsies, characterized by seizure onset and neurodevelopmental delay in infancy or childhood, often with additional neurological and syst...
09
DOI 10.1002/epi4.70369
Open DOI
Exploring medical food supplementation as an adjunct strategy for microbiota restoration and seizure reduction in CDKL5 deficiency disorder
Objectives: CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy characterized by early‐onset, treatment‐resistant seizures and severe neurodevelopmental impairment. Increasing evidence suggests that alteration...
10
DOI 10.1002/epi4.70364
Open DOI
Preliminary evidence of long‐term safety and effectiveness of anti‐ CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52‐week follow‐up retrospective study
Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world ...
Bibliographical & Catalog Notes
Published on behalf of the International League Against Epilepsy.
Sister publication to: Epilepsia.